MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
ENDRA Life Sciences Retained Earnings 2011-2026 | NDRA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -110 M | -103 M | -91.9 M | -81.9 M | -68.7 M | -57.3 M | -45.2 M | -27.7 M | -17.9 M | -12.5 M | -9.74 M | -7.46 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.46 M | -110 M | -52.9 M |
Quarterly Retained Earnings ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -107 M | -106 M | -104 M | -103 M | - | -96.9 M | -94.7 M | -91.9 M | -90.5 M | -87.4 M | -84.8 M | -81.9 M | -78.6 M | -75.1 M | -71.5 M | -68.7 M | -65.6 M | -62.9 M | -59.7 M | -57.3 M | -55.1 M | -57.3 M | -57.3 M | -45.2 M | -45.2 M | -45.2 M | -45.2 M | -27.7 M | -27.7 M | -27.7 M | -27.7 M | -17.9 M | -17.9 M | -17.9 M | -17.9 M | -12.5 M | -12.5 M | -12.5 M | -12.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -12.5 M | -107 M | -57.1 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 17.1 | 0.56 % | $ 181 M |  China |
 |
CareDx, Inc
CDNA
|
-735 M | $ 21.5 | 3.32 % | $ 1.15 B |  USA |
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Agilent Technologies
A
|
348 M | $ 114.52 | -0.86 % | $ 34.8 B | USA |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 1.55 | - | $ 2.06 M | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 24.81 | 1.31 % | $ 689 M | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 14.13 | -6.98 % | $ 427 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 112.85 | -4.63 % | $ 9.31 B |  Irlanda |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 135.78 | 7.13 % | $ 21.6 B | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 85.5 | 1.04 % | $ 5.77 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.8 | 1.05 % | $ 444 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 9.44 | 1.94 % | $ 1.21 B | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 417.54 | -0.27 % | $ 12 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.41 | 5.77 % | $ 390 M | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 165.78 | -0.71 % | $ 8.22 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 87.6 | 0.6 % | $ 11 B | USA |
 |
Personalis
PSNL
|
-550 M | $ 5.78 | 4.71 % | $ 342 M | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 2.12 | 7.07 % | $ 9.38 M | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 5.1 | -22.84 % | $ 213 M | USA |
 |
Soleno Therapeutics
SLNO
|
-431 M | $ 52.87 | 0.09 % | $ 2.69 B | USA |
 |
Thermo Fisher Scientific
TMO
|
59.2 B | $ 469.21 | -2.04 % | $ 177 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 60.4 | 3.34 % | $ 3.61 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.19 | 0.46 % | $ 5.03 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 255.84 | -0.37 % | $ 21.3 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 125.65 | 3.54 % | $ 5.88 B | USA |
 |
Natera
NTRA
|
-1.94 B | $ 207.28 | 0.54 % | $ 20.4 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.53 | 1.38 % | $ 2.07 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
Waters Corporation
WAT
|
10.4 B | $ 307.12 | -0.68 % | $ 18.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 192.67 | -0.79 % | $ 21.4 B | USA |